You just read:

First Multinational Study Initiated to Evaluate OFEV® (nintedanib) with Add-on of pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Dec 14, 2015, 08:00 ET